Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease

Movement Disorders

Volumn 27, Issue 5, 2012, Pages 617-626

  Postuma, Ronald B ^a,b   Aarsland, Dag ^c   Barone, Paolo ^d   Burn, David J ^e   Hawkes, Christopher H ^f   Oertel, Wolfgang ^g   Ziemssen, Tjalf ^h  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF SALERNO   (Italy)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g PHILIPPS UNIVERSITY MARBURG   (Germany)

^h UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Non motor; Parkinson's disease; Prediction; Sensitivity; Specificity

Indexed keywords

ALPHA SYNUCLEIN; ANTIDEPRESSANT AGENT;

ARTICLE; AUTONOMIC NEUROPATHY; COGNITIVE DEFECT; COLOR DISCRIMINATION; CONSTIPATION; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DYSMETRIA; ELECTRORETINOGRAPHY; EVOKED VISUAL RESPONSE; HUMAN; MILD COGNITIVE IMPAIRMENT; OPTICAL COHERENCE TOMOGRAPHY; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; PRODROME; PSYCHOPHARMACOTHERAPY; SACCADIC EYE MOVEMENT; SENSITIVITY AND SPECIFICITY; SMELLING DISORDER; SYMPTOM; VISUAL DISORDER;

BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS; MOTOR NEURONS; PARKINSON DISEASE;

EID: 84859874695     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24996     Document Type: Article

References (131)

1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
2. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol 2007; 113: 421-429.
3. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 2008; 70: 1042-1048.
4. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409-415.
5. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson's disease. Mov Disord 2010; 25( Suppl 1): S78-S82.
6. Dickson DW, Fujishiro H, Delledonne A, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 2008; 115: 437-444.
7. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol 2008; 34: 284-295.
8. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010; 1184: 188-195.
9. Parkkinen L, Pirttila T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol 2008; 115: 399-407.
10. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55: 138-142.
11. Hawkes CH, Shephard BC, Daniel SE. Olfactory dysfunction in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62: 436-146.
12. Hawkes CH, Shephard BC. Selective anosmia in Parkinson's disease? Lancet 1993; 341: 435-436.
13. Hawkes CH, Doty RL. Neurology of olfaction. Cambridge: Cambridge University Press; 2009.
14. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988; 38: 1237-1244.
15. Deeb J, Shah M, Muhammed N, et al. A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson's disease. QJM 2010; 103: 941-952.
16. Siderowf A, Newberg A, Chou KL, et al. [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 2005; 64: 1716-1720.
17. Pearce RK, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995; 10: 283-287.
18. Hawkes CH. Parkinson's disease and aging: same or different process? Mov Disord 2008; 23: 47-53.
19. Shah M, Muhammed N, Findley LJ, Hawkes CH. Olfactory tests in the diagnosis of essential tremor. Parkinsonism Relat Disord 2008; 14: 563-568.
20. Olichney JM, Murphy C, Hofstetter CR, et al. Anosmia is very common in the Lewy body variant of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1342-1347.
21. Silveira-Moriyama L, Hughes G, Church A, et al. Hyposmia in progressive supranuclear palsy. Mov Disord 2010; 25: 570-577.
22. Hawkes C. Olfaction in neurodegenerative disorder. Mov Disord 2003; 18: 364-372.
23. Silveira-Moriyama L, Schwingenschuh P, O'Donnell A, et al. Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry 2009; 80: 744-748.
24. Kruger S, Haehner A, Thiem C, Hummel T. Neuroleptic-induced parkinsonism is associated with olfactory dysfunction. J Neurol 2008; 255: 1574-1579.
25. Silveira-Moriyama L, Munhoz RP, de J Carvalho M, et al. Olfactory heterogeneity in LRRK2 related Parkinsonism. Mov Disord 2010; 25: 2879-2883.
26. Saunders-Pullman R, Hagenah J, Dhawan V, et al. Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord 2010; 25: 1364-1372.
27. Alcalay RN, Siderowf A, Ottman R, et al. Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology 2011; 76: 319-326.
28. Ferraris A, Ialongo T, Passali GC, et al. Olfactory dysfunction in Parkinsonism caused by PINK1 mutations. Mov Disord 2009; 24: 2350-2357.
29. Postuma RB, Montplaisir J. Transcranial ultrasound and olfaction in REM sleep behavior disorder: testing predictors of Parkinson's disease. Sleep Med 2010; 11: 339-340.
30. Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir J. Olfaction and Color vision identify impending neurodegeneration in REM behavior disorder. Ann Neurol 2011; 69: 811-818.
31. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005; 128( Pt 1): 126-137.
32. Ramjit AL, Sedig L, Leibner J, et al. The relationship between anosmia, constipation, and orthostasis and Parkinson's disease duration: results of a pilot study. Int J Neurosci 2010; 120: 67-70.
33. Postuma RB, Gagnon JF, Montplaisir J. Clinical prediction of Parkinson's disease-planning for the age of neuroprotection. J Neurol Neurosurg Psychiatry 2010; 81: 1008-1013.
34. Lee PH, Yeo SH, Kim HJ, Youm HY. Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. Mov Disord 2006; 21: 1975-1977.
35. Lee PH, Yeo SH, Yong SW, Kim YJ. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2007; 78: 1250-1252.
36. Iijima M, Osawa M, Momose M, et al. Cardiac sympathetic degeneration correlates with olfactory function in Parkinson's disease. Mov Disord 2010; 25: 1143-1149.
37. Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010; 133( Pt 6): 1747-1754.
38. Spiegel J, Hellwig D, Mollers MO, et al. Transcranial sonography and [123I]FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006; 129( Pt 5): 1188-1193.
39. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008; 63: 167-173.
40. Ross GW, Abbott RD, Petrovitch H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006; 21: 2062-2067.
41. Hawkes CH. The prodromal phase of sporadic Parkinson's disease: does it exist and if so how long is it? Mov Disord 2008; 23: 1799-1807.
42. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 79-84.
43. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-181.
44. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004; 19: 1196-1202.
45. Ross W, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk of future Parkinson's disease. Mov Disord 2005; 20( Supplement 10): S129-S130.
46. Lees AJ. When did Ray Kennedy's Parkinson's disease begin? Mov Disord 1992; 7: 110-116.
47. Marras C, Goldman S, Smith A, et al. Smell identification ability in twin pairs discordant for Parkinson's disease. Mov Disord 2005; 20: 687-693.
48. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. 'Sniffin' Sticks': olfactory performance assessed by the combined testing of odour identification, odor discrimination and olfactory threshold. Chem Senses 1997; 22: 39-52.
49. Schenck CH, Mahowald MW. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16 years after its formal identification in SLEEP. Sleep 2002; 25: 120-138.
50. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46: 388-393.
51. Iranzo A, Molinuevo JL, Santamaria J, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006; 5: 572-577.
52. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72: 1296-1300.
53. Iranzo A, Molinuevo JL, Santamaria J, et al. Sixty-four percent of patients with idiopathic REM sleep behavior disorder developed a neurological disorder after a mean clinical follow-up of seven years. Sleep 2008; 31: A280.
54. Schenck CH, Mahowald MW. REM behavior disorder (RBD): delayed emergence of parkinsonism and/or dementia in 65% of older men initially diagnosed with idiopathic RBD, and an analysis of the minimum and maximum tonic and/or phasic electromyographic abnormalities found during REM sleep. Sleep 2003; 26: A316.
55. Gagnon JF, Postuma RB, Mazza S, Doyon J, Montplaisir J. Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol 2006; 5: 424-432.
56. American Academy of Sleep Medicine. The International Classification of Sleep Disorders: Diagnostic and Coding Manual (ICSD-2). 2nd ed. Westchester, IL: American Academy of Sleep Medicine; 2005.
57. Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011; 12: 445-453.
58. Li SX, Wing YK, Lam SP, et al. Validation of a new REM sleep behavior disorder questionnaire (RBDQ-HK). Sleep Med 2010; 11: 43-48.
59. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov Disord 2007; 22: 2386-2393.
60. Postuma RB, Gagnon JF, Rompre S, Montplaisir J. Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease. Neurology 2010; 74: 239-244.
61. Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Idiopathic REM sleep behavior disorder in the transition to degenerative disease. Mov Disord 2009; 24: 2225-2232.
62. Postuma RB, Montplaisir J, Lanfranchi P, et al. Cardiac autonomic denervation in Parkinson's disease is linked to REM sleep behavior disorder. Mov Disord 2011; 26: 1529-1533.
63. Gagnon JF, Vendette M, Postuma RB, et al. Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann Neurol 2009; 66: 39-47.
64. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord 2008; 23: 1665-1672.
65. Postuma RB, Gagnon JF, Vendette M, Massicotte-Marquez J, Charland K, Montplaisir J. REM sleep behavior disorder in Parkinson's disease is associated with specific motor features. J Neurol Neurosurg Psychiatry 2008; 79: 1117-1121.
66. Postuma RB, Gagnon JF, Vendette M, Montplaisir J. Markers of neurodegeneration in idiopathic REM sleep behavior disorder and Parkinson disease. Brain 2009; 132: 2298-2307.
67. Postuma RB, Lanfranchi PA, Blais H, Gagnon JF, Montplaisir JY. Cardiac autonomic dysfunction in idiopathic REM sleep behavior disorder. Mov Disord 2010; 25: 2304-2310.
68. Iranzo A, Lomeña F, Stockner H, et al.; Sleep Innsbruck Barcelona (SINBAR) group. Decreased striatal dopamine transporters uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2010; 9: 1070-1077.
69. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66: 845-851.
70. Massicotte-Marquez J, Decary A, Gagnon JF, et al. Executive dysfunction and memory impairment in idiopathic REM sleep behavior disorder. Neurology 2008; 70: 1250-1257.
71. Ferini-Strambi L, Di Gioia MR, Castronovo V, Oldani A, Zucconi M, Cappa SF. Neuropsychological assessment in idiopathic REM sleep behavior disorder (RBD): does the idiopathic form of RBD really exist? Neurology 2004; 62: 41-45.
72. Fantini ML, Gagnon JF, Petit D, et al. Slowing of electroencephalogram in rapid eye movement sleep behavior disorder. Ann Neurol 2003; 53: 774-780.
73. Scherfler C, Frauscher B, Schocke M, et al. White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 2011; 69: 400-407.
74. Mazza S, Soucy JP, Gravel P, et al. Assessing whole brain perfusion changes in patients with REM sleep behavior disorder. Neurology 2006; 67: 1618-1622.
75. Unger MM, Belke M, Menzler K, et al. Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep 2010; 33: 767-773.
76. Ziemssen T, Fuchs G, Greulich W, Reichmann H, Schwarz M, Herting B. Treatment of dysautonomia in extrapyramidal disorders. J Neurol 2011; 258( Suppl 2): S339-S345.
77. Orimo S, Takahashi A, Uchihara T, et al. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 2007; 17: 24-30.
78. Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci 2010; 289: 74-80.
79. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001; 57: 456-462.
80. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009; 73: 1752-1758.
81. Mitsui J, Saito Y, Momose T, et al. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci 2006; 243: 101-104.
82. Spiegel J, Hellwig D, Farmakis G, et al. Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson's disease. Mov Disord 2007; 22: 1004-1008.
83. Oka H, Toyoda C, Yogo M, Mochio S. Cardiovascular dysautonomia in de novo Parkinson's disease without orthostatic hypotension. Eur J Neurol 2011; 18: 286-292.
84. Valappil RA, Black JE, Broderick MJ, et al. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease. Mov Disord 2010; 25: 2296-2303.
85. Schmidt C, Herting B, Prieur S, et al. Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm 2009; 116: 875-880.
86. Friedrich C, Rudiger H, Schmidt C, et al. Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord 2010; 25: 315-324.
87. Friedrich C, Rudiger H, Schmidt C, et al. Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Transm 2008; 115: 1527-1536.
88. Gasch J, Reimann M, Reichmann H, Rudiger H, Ziemssen T. Determination of baroreflex sensitivity during the modified Oxford maneuver by trigonometric regressive spectral analysis. PLoS One 2011; 6: e18061.
89. Reimann M, Friedrich C, Gasch J, Reichmann H, Rudiger H, Ziemssen T. Trigonometric regressive spectral analysis reliably maps dynamic changes in baroreflex sensitivity and autonomic tone: the effect of gender and age. PLoS One 2010; 5: e12187.
90. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996; 334: 71-76.
91. Mattock C, Marmot M, Stern G. Could Parkinson's disease follow intra-uterine influenza?: a speculative hypothesis. J Neurol Neurosurg Psychiatry 1988; 51: 753-756.
92. La Rovere MT, Pinna GD, Hohnloser SH, et al. Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials. Circulation 2001; 103: 2072-2077.
93. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006; 21: 148-158.
94. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008; 23: 183-189.
95. Santamaria J, Tolosa E, Valles A. Parkinson's disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 1986; 36: 1130-1133.
96. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641-1649.
97. O'sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 2008; 23: 101-106.
98. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 2006; 113: 211-220.
99. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 2003; 18: 414-418.
100. Alonso A, Rodriguez LA, Logroscino G, Hernan MA. Use of antidepressants and the risk of Parkinson's disease: a prospective study. J Neurol Neurosurg Psychiatry 2009; 80: 671-674.
101. Bower JH, Grossardt BR, Maraganore DM, et al. Anxious personality predicts an increased risk of Parkinson's disease. Mov Disord 2010; 25: 2105-2113.
102. Liepelt-Scarfone I, Behnke S, Godau J, et al. Relation of risk factors and putative premotor markers for Parkinson's disease. J Neural Transm 2011; 118: 579-585.
103. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. The retina in Parkinson's disease. Brain 2009; 132( Pt 5): 1128-1145.
104. Bodis-Wollner I, Tzelepi A. The push-pull action of dopamine on spatial tuning of the monkey retina: the effects of dopaminergic deficiency and selective D1 and D2 receptor ligands on the pattern electroretinogram. Vision Res 1998; 38: 1479-1487.
105. Blekher T, Weaver M, Rupp J, et al. Multiple step pattern as a biomarker in Parkinson disease. Parkinsonism Relat Disord 2009; 15: 506-510.
106. Bodis-Wollner I. Retinopathy in Parkinson disease. J Neural Transm 2009; 116: 1493-1501.
107. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Retinal thickness in Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 431-436.
108. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vision Res 2004; 44: 2793-2797.
109. Altintas O, Iseri P, Ozkan B, Caglar Y. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. Doc Ophthalmol 2008; 116: 137-146.
110. Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol 2009; 127: 737-741.
111. Moschos MM, Tagaris G, Markopoulos I, et al. Morphologic changes and functional retinal impairment in patients with Parkinson disease without visual loss. Eur J Ophthalmol 2011; 21: 24-29.
112. Aaker GD, Myung JS, Ehrlich JR, Mohammed M, Henchcliffe C, Kiss S. Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography. Clin Ophthalmol 2010; 4: 1427-1432.
113. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992; 42: 887-890.
114. Muller T, Kuhn W, Buttner T, et al. Colour vision abnormalities do not correlate with dopaminergic nigrostriatal degeneration in Parkinson's disease. J Neurol 1998; 245: 659-664.
115. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 2008; 70: 1017-1022.
116. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-844.
117. Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010; 75: 1062-1069.
118. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132( Pt 11): 2958-2969.
119. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005; 58: 773-776.
120. Sabbagh MN, Adler CH, Lahti TJ, et al. Parkinson disease with dementia: comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009; 23: 295-297.
121. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010; 9: 1200-1213.
122. Rosenthal E, Brennan L, Xie S, et al. Association between cognition and function in patients with Parkinson disease with and without dementia. Mov Disord 2010; 25: 1170-1176.
123. Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127( Pt 3): 550-560.
124. Elgh E, Domellof M, Linder J, Edstrom M, Stenlund H, Forsgren L. Cognitive function in early Parkinson's disease: a population-based study. Eur J Neurol 2009; 16: 1278-1284.
125. Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G. Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 2009; 72: 1121-1126.
126. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-39.
127. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
128. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22: 1689-1707.
129. Litvan I, Aarsland D, Adler CH, et al. MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011; 26: 1814-1824.
130. McKeith I. Commentary: DLB and PDD: the same or different? Is there a debate? Int Psychogeriatr 2009; 21: 220-224.
131. Molano J, Boeve B, Ferman T, et al. Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain 2010; 133( Pt 2): 540-556.